Evidence map›Paper›PMID 33025905›Full record

ArticleeLife2020

RUNX1 marks a luminal castration-resistant lineage established at the onset of prostate development.

Renaud Mevel, Ivana Steiner, Susan Mason, Laura Ca Galbraith, Rahima Patel, Muhammad Zh Fadlullah, Imran Ahmad, Hing Y Leung, Pedro Oliveira, Karen Blyth and 2 more

Open access · goldAbstract read
In one paragraph

Article in eLife, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Prostate organogenesis.Development (Cambridge, England) · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Renaud MevelCancer Research United Kingdom, Stem Cell Biology Group, Cancer Research United Kingdom Manchester Institute, The University of Manchester, Alderley Park, Alderley Edge, Macclesfield, United Kingdom.ORCID 0000-0002-2742-6576
Ivana SteinerCancer Research United Kingdom, Prostate Oncobiology Group, Cancer Research United Kingdom Manchester Institute, The University of Manchester, Alderley Park, Alderley Edge, Macclesfield, United Kingdom.ORCID 0000-0002-2744-1952
Susan MasonCancer Research United Kingdom Beatson Institute, Bearsden, Glasgow, United Kingdom.
Laura Ca GalbraithCancer Research United Kingdom Beatson Institute, Bearsden, Glasgow, United Kingdom.
Rahima PatelCancer Research United Kingdom, Stem Cell Biology Group, Cancer Research United Kingdom Manchester Institute, The University of Manchester, Alderley Park, Alderley Edge, Macclesfield, United Kingdom.
Muhammad Zh FadlullahCancer Research United Kingdom, Stem Cell Biology Group, Cancer Research United Kingdom Manchester Institute, The University of Manchester, Alderley Park, Alderley Edge, Macclesfield, United Kingdom.
Imran AhmadCancer Research United Kingdom Beatson Institute, Bearsden, Glasgow, United Kingdom.
Hing Y LeungCancer Research United Kingdom Beatson Institute, Bearsden, Glasgow, United Kingdom.
Pedro OliveiraDepartment of Pathology, The Christie NHS Foundation Trust, Manchester, United Kingdom.
Karen BlythCancer Research United Kingdom Beatson Institute, Bearsden, Glasgow, United Kingdom.
Esther BaenaCancer Research United Kingdom, Prostate Oncobiology Group, Cancer Research United Kingdom Manchester Institute, The University of Manchester, Alderley Park, Alderley Edge, Macclesfield, United Kingdom.
Georges LacaudCancer Research United Kingdom, Stem Cell Biology Group, Cancer Research United Kingdom Manchester Institute, The University of Manchester, Alderley Park, Alderley Edge, Macclesfield, United Kingdom.ORCID 0000-0002-5630-2417
University of Manchester · GBInstitute of Cancer Research · CACancer Research UK · GBCancer Research UK Scotland Institute · GBThe Christie NHS Foundation Trust · GB

Funding

Cancer Research UK 19565Cancer Research UK 19996Cancer Research UK 22904Cancer Research UK 29799Cancer Research UK C5759/A20971Cancer Research UK C596/A17196
6 · The paper itself

Abstract

The characterization of prostate epithelial hierarchy and lineage heterogeneity is critical to understand its regenerative properties and malignancies. Here, we report that the transcription factor RUNX1 marks a specific subpopulation of proximal luminal cells (PLCs), enriched in the periurethral region of the developing and adult mouse prostate, and distinct from the previously identified NKX3.1

Indexed as

AnimalsCell LineageCore Binding Factor Alpha 2 SubunitEpitheliumMaleMiceOrchiectomyProstateCore Binding Factor Alpha 2 SubunitRunx1 protein, mousedevelopmentdevelopmental biologyintrinsic castration-resistancemouseprostateproximal luminal cellsregenerative medicineRUNX1single-cell RNA-seqstem cells

Identifiers

PMID33025905
PMCPMC7644213
OpenAlexW3091778672

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.